ValuEngine Downgrades Novo Nordisk A/S (NYSE:NVO) to Sell

Share on StockTwits

Novo Nordisk A/S (NYSE:NVO) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Tuesday, ValuEngine reports.

A number of other equities analysts have also weighed in on the company. Jefferies Financial Group lowered Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a research report on Friday, August 30th. Deutsche Bank cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price target for the company. in a research report on Thursday, June 20th. Zacks Investment Research upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price target for the company in a research report on Monday, July 15th. Barclays upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price target for the company in a research report on Tuesday, June 11th. Finally, Pareto Securities upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Monday, August 5th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the stock. Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $111.58.

Shares of Novo Nordisk A/S stock traded down $1.07 during trading on Tuesday, reaching $49.77. 69,062 shares of the company traded hands, compared to its average volume of 1,421,670. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.04 and a quick ratio of 0.73. Novo Nordisk A/S has a 1-year low of $41.23 and a 1-year high of $53.55. The company has a 50 day moving average price of $50.81 and a 200-day moving average price of $49.93. The firm has a market capitalization of $119.25 billion, a PE ratio of 19.67, a P/E/G ratio of 2.16 and a beta of 0.57.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Friday, August 9th. The company reported $0.61 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.61. Novo Nordisk A/S had a net margin of 32.16% and a return on equity of 75.16%. The company had revenue of $4.52 billion for the quarter, compared to the consensus estimate of $4.41 billion. Equities research analysts expect that Novo Nordisk A/S will post 2.45 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tdam USA Inc. grew its holdings in shares of Novo Nordisk A/S by 1.5% during the first quarter. Tdam USA Inc. now owns 14,766 shares of the company’s stock worth $772,000 after purchasing an additional 214 shares in the last quarter. Sunbelt Securities Inc. grew its stake in Novo Nordisk A/S by 1.9% in the 2nd quarter. Sunbelt Securities Inc. now owns 12,959 shares of the company’s stock worth $661,000 after buying an additional 238 shares in the last quarter. Silvercrest Asset Management Group LLC grew its stake in Novo Nordisk A/S by 1.0% in the 2nd quarter. Silvercrest Asset Management Group LLC now owns 24,419 shares of the company’s stock worth $1,246,000 after buying an additional 238 shares in the last quarter. Ballentine Partners LLC grew its stake in Novo Nordisk A/S by 3.5% in the 1st quarter. Ballentine Partners LLC now owns 7,220 shares of the company’s stock worth $378,000 after buying an additional 242 shares in the last quarter. Finally, Rehmann Capital Advisory Group grew its stake in Novo Nordisk A/S by 27.3% in the 2nd quarter. Rehmann Capital Advisory Group now owns 1,190 shares of the company’s stock worth $61,000 after buying an additional 255 shares in the last quarter. Hedge funds and other institutional investors own 7.36% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Read More: Understanding Options Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Royal Dutch Shell  Stock Rating Lowered by ValuEngine
Royal Dutch Shell Stock Rating Lowered by ValuEngine
ValuEngine Downgrades Novo Nordisk A/S  to Sell
ValuEngine Downgrades Novo Nordisk A/S to Sell
HICL Infrastructure  Share Price Passes Above 50-Day Moving Average of $162.49
HICL Infrastructure Share Price Passes Above 50-Day Moving Average of $162.49
Moneta Group Investment Advisors LLC Takes Position in QUALCOMM, Inc.
Moneta Group Investment Advisors LLC Takes Position in QUALCOMM, Inc.
Lowe’s Companies  Upgraded by ValuEngine to Buy
Lowe’s Companies Upgraded by ValuEngine to Buy
Moneta Group Investment Advisors LLC Grows Stock Holdings in J M Smucker Co
Moneta Group Investment Advisors LLC Grows Stock Holdings in J M Smucker Co


 
© 2006-2019 Zolmax.